Science Explorer Back to mapMap
Discussion
Researcher · St. Eugenio Hospital · Italy

Elisabetta Abruzzese

Elisabetta Abruzzese publishes mostly in Hematology, Genetics and Rheumatology, on topics such as Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research and Eosinophilic Disorders and Syndromes.

ORCID 0000-0001-5228-6491 OpenAlex
World rank
#712,593
of 7,710,434 ranked researchers
Rank in Italy
#21,268
of 242,206
Works
536
Citations
12k
Citations per work
23.0
h-index
52
i10-index 192Top 3.2% in Hematology
Elisabetta Abruzzese

What does Elisabetta Abruzzese research?

Elisabetta Abruzzese's work is mostly in Medicine (80%), Biochemistry, Genetics and Molecular Biology (3%).

Health Sciences: 431 works · 80.4% of their workMedicine: 431 works · 80.4% of their workHematology: 192 works · 35.8% of their workGenetics: 130 works · 24.3% of their workRheumatology: 46 works · 8.5% of their workPublic Health, Environmental and Occupational Health: 35 works · 6.6% of their workOncology: 28 works · 5.2% of their workEverything else: 90 works · 16.8% of their workLife Sciences: 15 works · 2.8% of their workBiochemistry, Genetics and Molecular Biology: 15 works · 2.8% of their workMolecular Biology: 15 works · 2.8% of their workTHEIR WORKElisabettaAbruzzese536works
Life Sciences3%Health Sciences80%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine43180.4%
  2. Everything else9016.8%
    1. Biochemistry, Genetics and Molecular Biology152.8%
  1. 1Hematology36% of their works
  2. 2Genetics24% of their works
  3. 3Rheumatology8% of their works
  4. 4Public Health, Environmental and Occupational Health7% of their works
  5. 5Oncology5% of their works
  6. 6Molecular Biology3% of their works

Research topics

Which keywords describe Elisabetta Abruzzese's research?

The keywords of their largest research topics: Prognostic Factors, BCR-ABL, Imatinib, Rituximab, Chronic Lymphocytic Leukemia, Genomic Aberrations, Classification and Fusion Genes.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Prognostic Factors4233 topics
  2. BCR-ABL4111 topic
  3. Imatinib4111 topic
  4. Rituximab2882 topics
  5. Chronic Lymphocytic Leukemia2501 topic
  6. Genomic Aberrations2501 topic
  7. Classification1632 topics
  8. Fusion Genes1251 topic
  9. Hypereosinophilic Syndrome1251 topic
  10. JAK2 Mutation961 topic
  11. Myelofibrosis961 topic
  12. Acute Lymphoblastic Leukemia911 topic
  13. Childhood Cancer911 topic
  14. AML821 topic
  15. Acute Myeloid Leukemia821 topic
  16. Lymphoma381 topic
  17. Molecular Profiling381 topic
  18. Breast Cancer251 topic
  19. HER2251 topic

Where does Elisabetta Abruzzese work?

Elisabetta Abruzzese's main affiliation in the publication record is St. Eugenio Hospital, Italy.

How many publications and citations does Elisabetta Abruzzese have?

OpenAlex counts 536 works and 12,351 citations for Elisabetta Abruzzese, an h-index of 52, ranking #712,593 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Elisabetta Abruzzese. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.